Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
| Revenue (TTM) | $298.30M |
| Gross Profit (TTM) | $233.47M |
| EBITDA | $153.71M |
| Operating Margin | 53.30% |
| Return on Equity | 65.00% |
| Return on Assets | 13.70% |
| Revenue/Share (TTM) | $2.25 |
| Book Value | $4.34 |
| Price-to-Book | 3.48 |
| Price-to-Sales (TTM) | 6.56 |
| EV/Revenue | 5.58 |
| EV/EBITDA | 10.57 |
| Quarterly Earnings Growth (YoY) | 56.30% |
| Quarterly Revenue Growth (YoY) | 24.40% |
| Shares Outstanding | $128.60M |
| Float | $126.24M |
| % Insiders | 7.53% |
| % Institutions | 60.70% |
Volatility is currently contracting
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study's primary endpoint is the proportion of patients achieving complete renal response (CRR).
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH's valuation and future pipeline or strategic optionality.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Silver prices surged 7% Monday to the highest since March.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AUPH and any ticker you trade — then tracks every position and per-strategy win rate.
